menu
    • menu
    [{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rosuvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ AcuteBio","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ AcuteBio"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Clopidogrel Bisulfate

    Menu

    Clopidogrel Bisulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Japan
                            Booth #5N-12
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Aspirin,Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy’s Launches Rozat Gold FDC in India (Aspirin, Rosuvastatin, Clopidogrel)

                            Details : Rozat Gold is a fixed dose combination medicine consisting aspirin, rosuvastatin & clopidogrel. It is indicated for the treatment of coronary artery diseases.

                            Product Name : Rozat Gold

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 18, 2021

                            Lead Product(s) : Aspirin,Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Clopidogrel,Aspirin

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Indication for Plavix® (clopidogrel) Now Approved in the European Union

                            Details : Plavix (clopidogrel) is a P2Y12 platelet inhibitor which is indicated for the treatment of in adult patients with moderate to high-risk transient ischemic attack.

                            Product Name : Plavix

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 09, 2021

                            Lead Product(s) : Clopidogrel,Aspirin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            USV Private Limited

                            India arrow
                            Interphex
                            Not Confirmed

                            USV Private Limited

                            India arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosuvastatin,Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients

                            Details : Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.

                            Product Name : Roseday CV

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 24, 2023

                            Lead Product(s) : Rosuvastatin,Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ascendia Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Ascendia Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascendia Pharmaceutical Solutions Develops Nanoemulsion IV Clopidogrel

                            Details : ASD-002 (clopidogrel) is a P2Y12 platelet inhibitor which is being investigated for the treatment of coronary artery disease.

                            Product Name : ASD-002

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 10, 2023

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ascendia Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Ascendia Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : AcuteBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval

                            Details : ASD-002 (clopidogrel) being developed by EmulSol nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval for Acute Coronary Syndrome.

                            Product Name : ASD-002

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 23, 2023

                            Lead Product(s) : Clopidogrel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : AcuteBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth